Purchase Order 75F40121P00097
Award Date 5/10/21
Potential Completion Date 7/20/26
Potential Value $577K
Federal Agency
Awardee
Ultimate Awardee
Not listed NAICS Category
PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
San Diego, CA 92122, USA
Solicitation Procedures
Only One Source
Number Of Offers Received
1
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- This is a firm fixed-price purchase order contract awarded by the Food and Drug Administration (FDA) to Illumina, Inc., a biotechnology company specializing in genetic sequencing and genomic analysis technologies. The $780,844.00 contract is for the provision of Illumina's NovaSeq 6000 sequencing system and associated services over a period ending on September 26, 2029. The contract does not utilize any set-aside designations. Illumina has been a key technology provider for various federal...
- This is a firm fixed-price purchase order awarded by the Food and Drug Administration (FDA), a civilian federal agency, to Illumina, Inc., a for-profit manufacturer of genomic analysis technologies. The contract, with a ceiling value of $417,372.48, is for preventative maintenance services on Illumina's NextSeq 2000 and NextSeq 500 sequencing platforms. The award does not utilize a set-aside designation. Illumina is a leading provider of genetic sequencing instruments, reagents, and...
- This is a firm fixed-price purchase order contract awarded by the Food and Drug Administration (FDA) to Illumina, Inc., a leading manufacturer of genetic sequencing and genomic analysis technologies. The contract is for NEXTSEQ 500 comprehensive plan service maintenance for two NextSeq 500 sequencing systems at the FDA's location in Berwyn Heights, Maryland. The contract has a ceiling value of $265,801.32 and a period of performance through September 30, 2021. This contract does not have a...
- This is a firm fixed price purchase order contract awarded by the Food and Drug Administration (FDA) to Illumina, Inc., a manufacturer of sequencing and array-based solutions for genetic and genomic analysis. The contract is for the delivery of a "HIGH-THROUGHPUT DESKTOP SEQUENCER WITH DATA ANALYSIS SYSTEM" and has a ceiling value of $426,000.30. There is no set-aside designation for this contract. Illumina has previously provided a range of sequencing systems, reagents, and...
- This firm fixed-price purchase order was awarded by the Food and Drug Administration (FDA) to Illumina, Inc., a manufacturer of genetic sequencing instruments and reagents, to provide a diagnostic check and system upgrades for the MiSeq Whole Genome Sequencer at six FDA laboratories. The $84,733.20 contract has a completion date of December 31, 2022 and was sole-sourced to Illumina due to the proprietary nature of the MiSeq technology. Illumina has previously provided sequencing systems,...
- This is a firm fixed-price purchase order contract awarded by the Food and Drug Administration (FDA) to Illumina, Inc., a leading manufacturer of genetic sequencing and genomic analysis technologies. The contract is for the procurement of the MiSeq whole genome sequencing instrument, a genome sequencer, with a ceiling value of $166,207.78 and a period of performance through June 30, 2029. The contract is not set aside for any specific business designation. Illumina holds multiple federal...
- This is a firm fixed-price purchase order contract awarded by the Food and Drug Administration (FDA) to Illumina, Inc., a leading manufacturer of genetic sequencing and genomic analysis technologies. The contract is for the service and maintenance of one Illumina MiSeq sequencing system, with a ceiling value of $34,972.40 and a performance period ending on September 24, 2024. Illumina, a for-profit organization and manufacturer of goods, has been awarded numerous prime federal contracts and...
- This is a $142,142.04 firm fixed-price purchase order awarded by the Food and Drug Administration (FDA) to Illumina, Inc., a for-profit biotechnology manufacturer, for annual maintenance of the agency's Illumina NextSeq2000 genetic sequencing instruments. The contract does not have a set-aside designation. Illumina has two significant Indefinite Delivery Vehicles (IDVs) with the U.S. Department of Agriculture and Department of Veterans Affairs for providing a range of genomic sequencing...
- This is a firm fixed-price purchase order contract awarded by the Food and Drug Administration (FDA) to Illumina, Inc., a leading manufacturer of genetic sequencing and genomic analysis technologies. The contract, valued at $199,714.00, is for the provision of NextSeq 550 sequencing instrument service and qualification. The contract has an ultimate completion date of August 30, 2029. Illumina, headquartered in San Diego, California, is the prime contractor and there is no set-aside designation...
- This is a firm fixed price purchase order contract awarded by the Food and Drug Administration (FDA) to Illumina, Inc., a leading manufacturer of genetic sequencing and genomic analysis technologies, for a service agreement for a NextSeq 500 instrument. The contract has a ceiling value of $185,733.00 and a period of performance through September 11, 2024. It does not utilize a set-aside designation. The contract appears to be part of Illumina's broader federal contracting portfolio, which...